Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma

Tai Cheng-Jeng; Huang Ming-Te; Wu Chih-Hsiung; Wang Chien-Kai; Tai Chen-Jei; Chang Chun-Chao; Hsieh Cheng-I.; Chang Yu-Jia; Wu Chang-Jer; Kuo Li-Jen; Wei Po-Lei; Chen Ray-Jade; Chiou Hung-Yi

首页> 外文期刊>Medicine. >Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma

【24h】

Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma

机译：两种靶向药物（贝伐单抗加西妥昔单抗）的组合可改善胰腺癌的治疗反应

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The objective of this study is to evaluate the efficacy and safety profiles of the targeted medications, bevacizumab and cetuximab, in combination with cytostatic drugs in patients with locally advanced or metastatic pancreatic cancer.

机译：这项研究的目的是评估靶向药物贝伐单抗和西妥昔单抗联合细胞抑制药物在局部晚期或转移性胰腺癌患者中的疗效和安全性。

著录项

来源
《Medicine. 》 |2016年第15期| 共6页
作者
Tai Cheng-Jeng; Huang Ming-Te; Wu Chih-Hsiung; Wang Chien-Kai; Tai Chen-Jei; Chang Chun-Chao; Hsieh Cheng-I.; Chang Yu-Jia; Wu Chang-Jer; Kuo Li-Jen; Wei Po-Lei; Chen Ray-Jade; Chiou Hung-Yi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生 ;
关键词

相似文献

外文文献
中文文献
专利

1. Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma [J] . Tai Cheng-Jeng, Huang Ming-Te, Wu Chih-Hsiung, Medicine. . 2016 ,第15期

机译：两种靶向药物（贝伐单抗加西妥昔单抗）的组合可改善胰腺癌的治疗反应
2. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. [J] . Sharkey RM, Karacay H, Govindan SV, Molecular cancer therapeutics . 2011 ,第6期

机译：涉及不同或相同靶标的放射免疫疗法和化学免疫疗法的组合改善了人胰腺癌异种移植模型的治疗。
3. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma [J] . Sch?ferH., DieckmannC., KorniienkoO., Cancer letters . 2012 ,第1期

机译：L1CAM抗体和细胞生长抑制药物的联合治疗可改善胰腺癌和卵巢癌的治疗反应
4. Targeting of Epidermal Growth Factor Receptor (EGFR)-positive pancreatic cancer cell lines with cetuximab-conjugated near-infrared silver sulphide quantum dots [C] . Peter L. Labib, Elnaz Yaghini, Mahshid Hashemkhani, International Photodynamic Association World Congress;Society of Photo-Optical Instrumentation Engineers;International Photodynamic Association . 2019

机译：西妥昔单抗缀合的近红外硫化银量子点靶向表皮生长因子受体（EGFR）阳性胰腺癌细胞系
5. Multimodal Therapeutic Strategy for Pancreatic Cancer: EGFR-Targeted Gelatin-Based Nanoparticles for Combination Wild-Type p53 Gene and Cytotoxic Drug Delivery. [D] . Xu, Jing. 2013

机译：胰腺癌的多模式治疗策略：结合野生型p53基因和细胞毒性药物递送的EGFR靶向明胶纳米颗粒。
6. Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma [O] . Cheng-Jeng Tai, Ming-Te Huang, Chih-Hsiung Wu, -1

机译：两种靶向药物（贝伐单抗加西妥昔单抗）的组合可改善胰腺癌的治疗反应
7. Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma [O] . Cheng-Jeng Tai, Ming-Te Huang, Chih-Hsiung Wu, 2016

机译：两种靶向药物（Bevacizumab Plus Cetuximab）的组合改善了胰腺癌的治疗反应

Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅